ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301

ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301

ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to develop and commercialize its drug candidate ABL301 for the treatment of Parkinson’s disease. According to the South Korean biotech firm, ABL301 is a pre-clinical stage bispecific antibody, which targets alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R). […]

Sanofi to acquire UK-based biopharma company Kymab in $1.4bn worth deal

Sanofi to acquire UK-based biopharma company Kymab in $1.4bn worth deal

Sanofi acquisition of Kymab : French pharma giant Sanofi has signed a deal worth up to $1.45 billion to acquire Kymab, a UK-based clinical-stage biopharma company focused on developing fully human monoclonal antibodies, particularly for immune-mediated diseases, and immuno-oncology therapeutics. The consideration includes an upfront payment of around $1.1 billion and up to $350 million […]

Sanofi to acquire US biopharma company Principia Biopharma for $3.7bn

Sanofi to acquire US biopharma company Principia Biopharma for $3.7bn

Sanofi acquisition of Principia Biopharma : French pharma giant Sanofi has signed an all-cash deal worth $3.68 billion to acquire Principia Biopharma, a late-stage California-based biopharma company, engaged in developing treatments for immune-mediated diseases. As per the terms of the deal, Sanofi will acquire all of the outstanding shares of the US biopharma company for […]

Perrigo acquires skincare and hair loss treatment brands from Sanofi

Perrigo acquires skincare and hair loss treatment brands from Sanofi

Ireland-based Perrigo Company has agreed to acquire three over-the-counter (OTC) skincare and hair loss treatment brands sold across Eastern Europe, namely Emolium, Iwostin, and Loxon, from French pharma giant Sanofi. Financial terms of the deal were not disclosed by the parties. According to Perrigo Company, the products to be acquired have trailing 12 months net […]

Sanofi, GSK to supply 60 million doses of COVID-19 vaccine to UK

Sanofi, GSK to supply 60 million doses of COVID-19 vaccine to UK

Pharma majors Sanofi and GlaxoSmithKline (GSK) have reached an agreement with the UK government for supplying up to 60 million doses of their jointly developed COVID-19 vaccine candidate. The agreement will be subject to a final contract issued by the British government. The COVID-19 vaccine candidate has been developed by Sanofi in partnership with British […]

Vaccine giants Sanofi, GSK announce COVID-19 vaccine partnership

Vaccine giants Sanofi, GSK announce COVID-19 vaccine partnership

French pharma company Sanofi has announced a COVID-19 vaccine partnership with GlaxoSmithKline (GSK) to develop an adjuvanted vaccine for the novel coranavirus, by combining their drug discovery technologies. Sanofi will provide its S-protein Covid-19 antigen based on recombinant DNA technology to the partnership. The technology is said to be used for generating an exact genetic […]

Baxter to acquire Seprafilm Adhesion Barrier from Sanofi for $350m

Baxter to acquire Seprafilm Adhesion Barrier from Sanofi for $350m

Baxter International, a US-based health care company, has signed a deal worth $350 million to acquire Seprafilm Adhesion Barrier and related assets from French pharma company Sanofi, in a move to expand its advanced surgery portfolio. Seprafilm Adhesion Barrier is a medical device, which has FDA approval for preventing adhesion in patients going through abdominal […]

Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer

Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer

Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), which is one of the most commonly diagnosed skin cancers. Libtayo, which is a fully-human monoclonal antibody targeting the immune checkpoint receptor programmed cell death […]